Vestibular DiseaseUVISNCT07297355
Four Ways to Be Dizzy: When Physiology Fails to Explain Disability Insights From the UVIS International Survey
An observational study of Vestibular Disease and Vestibular Dysfunction, run by Université Catholique de Louvain at 3 sites in 3 countries.
Trial summary
The aim of this international study is to better understand how vestibular disorders affect daily life, including physical balance, vision and movement tolerance, emotional wellbeing, and cognitive functioning. Read more about this study
- Who is it for?
- Ages 18 to 90 yearsHealthy volunteers can take part
- Conditions the study is for
- Vestibular Disease, Vestibular Dysfunction
- How many people
- 250 participants
- Where
- 3 sitesin 3 countries
- Study dates
- 10 Nov 2023to 3 Aug 2025
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Vestibular loss diagnosed by senior ENT doctors
Who may be able to join
- Age between 18 and 90 years old.
- Vestibular loss diagnosed by senior ENT doctors
- Age between 18 and 90 years old.
Who cannot join
- Previous neurological disorders (stroke, dementia, …)
- Current medication interfering with the testing (reducing reaction time).
- Visual difficulties interfering with the testing (Visual field reduction,…)
- Age below 18 years old.
- For healthy controls :
- Previous neurological disorders (stroke, dementia, …)
Show all 11Show fewer
- Current medication interfering with the testing (reducing reaction time)
- Visual difficulties interfering with the testing (Visual field reduction,…)
- Vertigo or balance complains or an history of previous vestibular disorder.
- Age below 18 years old.
- Not being able to understand the consigns of the task.
Trial locations and contacts
3 sites in 3 countries.
3 sites in 3 countries
United States1 site
Medical University of South Carolina
Charleston, South Carolina, 29425
About this study
Official title: UVIS - UCLouvain Vertigo International Survey
The aim of this international study is to better understand how vestibular disorders affect daily life, including physical balance, vision and movement tolerance, emotional wellbeing, and cognitive functioning. Vestibular disorders are common but often difficult to diagnose because symptoms vary widely from one patient to another. To improve clinical care, we need large-scale information on the real-world experience of patients across different countries and clinical settings.
The UCLouvain Vertigo International Survey (UVIS) collects standardized information from adults with confirmed vestibular disorders, including questionnaires about dizziness-related handicap, emotional symptoms, and cognitive-vestibular complaints. Ear-nose-throat (ENT) specialists also provide routine clinical test results, such as caloric testing, vestibular evoked myogenic potentials (cVEMP and oVEMP), video head impulse tests (vHIT), and posturography. By combining these data, the study aims to identify different patient profiles and to examine how subjective symptoms relate to the physiological function of the vestibular system.
Read more
Participants take part during their routine clinical visit. They complete short questionnaires (on dizziness, anxiety, depression, cognitive symptoms, and daily functioning), and their ENT specialist encodes the results of the vestibular tests already performed as part of their usual care. No additional medical tests are required for the study.
By comparing data from several centers in Belgium, France, and the United States, this project seeks to provide a more complete picture of vestibular disorders worldwide and to support the development of better diagnostic tools and more personalized rehabilitation strategies.
- Conditions
- Vestibular Disease, Vestibular Dysfunction
- Medical subject headings
- Vestibular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Vestibular | Patients with vestibular loss diagnosed by senior ENT doctors with the gold standard ENT measures (caloric testing, head impulse test and/or vestibular evoked myogenic potential, ocular and cervical) | |
| Healthy controls | People with no vestibular loss |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assessment of dizziness-related handicap
DHI - Dizziness Handicap Inventory (25 items; physical, functional, emotional subscales). Scores 0-100. Higher scores = greater handicap.
Measured: Through the entire study, approximately 36 months.
Assessment of emotional symptoms
HADS - Hospital Anxiety and Depression Scale (14 items; Anxiety and Depression subscales). Scores 0-21 per subscale. Higher scores = more symptoms
Measured: Through the entire study, approximately 36 months.
Assessment of cognitive-vestibular complaints
NVI - Neuropsychological Vertigo Inventory (22 items assessing cognitive-vestibular symptoms: attention, memory, spatial orientation, visuospatial abilities). Higher scores = more complaints
Measured: Through the entire study, approximately 36 months.
Secondary outcomes (4)
Vestibular Physiological Function - canal paresis percentage
Measured: Through the entire study, approximately 36 months.
Vestibular Physiological Function - cVEMP and oVEMP
Measured: Through the entire study, approximately 36 months.
Vestibular Physiological Function - video Head Impulse Test
Measured: Through the entire study, approximately 36 months.
Vestibular Physiological Function - Posturography
Measured: Through the entire study, approximately 36 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2025
- Study start10 Nov 2023
- Primary completion3 Aug 2025
- Study completion3 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vestibular DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 250 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07297355
- Sponsor's protocol ID
- ABMA-3
- Acronym
- UVIS
- Status last verified
- Dec 2025
- First submitted
- 1 Dec 2025
- Last updated
- 22 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- UVIS - UCLouvain Vertigo International Survey
- ClinicalTrials.gov ID
- NCT07297355
- Acronym / sponsor ID
- UVIS / ABMA-3
- Conditions
- Vestibular Disease, Vestibular Dysfunction
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 250 participants (actual)
- Lead sponsor
- Université Catholique de LouvainUniversity, hospital or other
- Study start
- 10 Nov 2023 (actual)
- Primary completion
- 3 Aug 2025 (actual)
- Study completion
- 3 Aug 2025 (actual)
- First posted
- 22 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this international study is to better understand how vestibular disorders affect daily life, including physical balance, vision and movement tolerance, emotional wellbeing, and cognitive functioning. Vestibular disorders are common but often difficult to diagnose because symptoms vary widely from one patient to another. To improve clinical care, we need large-scale information on the real-world experience of patients across different countries and clinical settings.
The UCLouvain Vertigo International Survey (UVIS) collects standardized information from adults with confirmed vestibular disorders, including questionnaires about dizziness-related handicap, emotional symptoms, and cognitive-vestibular complaints. Ear-nose-throat (ENT) specialists also provide routine clinical test results, such as caloric testing, vestibular evoked myogenic potentials (cVEMP and oVEMP), video head impulse tests (vHIT), and posturography. By combining these data, the study aims to identify different patient profiles and to examine how subjective symptoms relate to the physiological function of the vestibular system.
Participants take part during their routine clinical visit. They complete short questionnaires (on dizziness, anxiety, depression, cognitive symptoms, and daily functioning), and their ENT specialist encodes the results of the vestibular tests already performed as part of their usual care. No additional medical tests are required for the study.
By comparing data from several centers in Belgium, France, and the United States, this project seeks to provide a more complete picture of vestibular disorders worldwide and to support the development of better diagnostic tools and more personalized rehabilitation strategies.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Vestibular | – | –Patients with vestibular loss diagnosed by senior ENT doctors with the gold standard ENT measures (caloric testing, head impulse test and/or vestibular evoked myogenic potential, ocular and cervical) |
| Healthy controls | – | –People with no vestibular loss |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Vestibular loss diagnosed by senior ENT doctors
Key inclusion criteria (3 listed)
- Age between 18 and 90 years old.
- Vestibular loss diagnosed by senior ENT doctors
- Age between 18 and 90 years old.
Key exclusion criteria (11 listed)
- Previous neurological disorders (stroke, dementia, …)
- Current medication interfering with the testing (reducing reaction time).
- Visual difficulties interfering with the testing (Visual field reduction,…)
- Age below 18 years old.
- Previous neurological disorders (stroke, dementia, …)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assessment of dizziness-related handicap
Time frame: Through the entire study, approximately 36 months.
DHI - Dizziness Handicap Inventory (25 items; physical, functional, emotional subscales). Scores 0-100. Higher scores = greater handicap.
Assessment of emotional symptoms
Time frame: Through the entire study, approximately 36 months.
HADS - Hospital Anxiety and Depression Scale (14 items; Anxiety and Depression subscales). Scores 0-21 per subscale. Higher scores = more symptoms
Assessment of cognitive-vestibular complaints
Time frame: Through the entire study, approximately 36 months.
NVI - Neuropsychological Vertigo Inventory (22 items assessing cognitive-vestibular symptoms: attention, memory, spatial orientation, visuospatial abilities). Higher scores = more complaints
4 secondary outcomes
Vestibular Physiological Function - canal paresis percentage
Time frame: Through the entire study, approximately 36 months.
Vestibular Physiological Function - cVEMP and oVEMP
Time frame: Through the entire study, approximately 36 months.
Vestibular Physiological Function - video Head Impulse Test
Time frame: Through the entire study, approximately 36 months.
Vestibular Physiological Function - Posturography
Time frame: Through the entire study, approximately 36 months.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Vestibular Disease
Active, not recruiting
Comparative Effects of Vestibular Rehabilitation With and Without Cervical JPS Training in Stroke Patients
Stroke
RecruitingObservational study
Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.
Hearing Loss, Deafness
Not yet recruitingPhase 2
Selumetinib for NF2-Related Schwannomatosis
Neurofibromatosis Type 2, NF2
RecruitingPhase 2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
Neurofibromatosis Type 2, Vestibular Schwannoma
Recruiting
Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device
Hearing Loss, Dizziness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Vestibular Disease and Vestibular Dysfunction, run by Université Catholique de Louvain at 3 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States, Belgium, France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assessment of dizziness-related handicap (time frame: Through the entire study, approximately 36 months.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2025.